Outlook Therapeutics
OTLK
63 hedge funds and large institutions have $50.2M invested in Outlook Therapeutics in 2021 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 14 closing their positions.
100% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 14
66% more capital invested
Capital invested by funds: $30.3M → $50.2M (+$19.9M)
29% more funds holding
Funds holding: 49 → 63 (+14)
0.19% more ownership
Funds ownership: 0.39% → 0.58% (+0.19%)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.11M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.8M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.64M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.87M |
| 2 |
Two Sigma Investments
New York
|
-$820K |
| 3 |
Millennium Management
New York
|
-$450K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$373K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$319K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VFA
76
Valeo Financial Advisors
Carmel,
Indiana
| – | -$2K | -50 | Closed |
|
77
Wells Fargo
San Francisco,
California
| – | -$1.34K | -29 | -94% |
|
OTLK Hedge Fund Activity: Q2 2021 in Review
63 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2021, worth a combined $50.2M — up 66% from $30.3M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new OTLK positions and 14 closed out — a net gain of 14 holders — while 11 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $9.3M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.87M sold.
- 63 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2021, up from 49 in Q1 2021.
- Funds reported $50.2M of Outlook Therapeutics stock for Q2 2021, up 66% quarter-over-quarter.
- 28 funds opened new Outlook Therapeutics positions in Q2 2021 and 14 closed out, a net change of +14 holders.
- The largest Outlook Therapeutics buyer in Q2 2021 was BlackRock, an estimated $9.3M added.
- The largest Outlook Therapeutics seller in Q2 2021 was Renaissance Technologies, an estimated $1.87M sold.
Based on aggregated 13F filings for Q2 2021.